S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
CLRB · Cellectar Biosciences, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Cellectar Biosciences Inc (CLRB)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$1.28
+0.06
(+4.92%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$1.28
$1.26
$1.30
52-WEEK RANGE
$1.28
$1.12
$4.70
What's happening
- CLRB is up 4.92% today, trading at $1.28. — Live quote
- Volume today (3,895) is well below its 3-month average of 93,190. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.57 actual vs. $-0.49 estimated (-15.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 6
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CLRB
-58.31%
vs S&P 500
-71.08%
1-YEAR RETURN
CLRB
-71.33%
vs S&P 500
-85.89%
6-MONTH RETURN
CLRB
-59.14%
3-MONTH RETURN
CLRB
-52.33%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.57
Est. $-0.49
MISS -15.6%
2026-04-26 (Q1 2026)
$-1.30
Est. $-1.92
BEAT +32.4%
2026-01-26 (Q4 2025)
$-1.29
Est. $-2.34
BEAT +44.9%
2025-10-26 (Q3 2025)
$-1.41
Est. $-2.58
BEAT +45.3%
Valuation Measures & Ratios
Enterprise Value4-$22.4M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)129.18
Price / Book70.74
EV4 / Revenue-248.53
EV4 / EBITDA—
Profit Margin-24744.44%
Operating Margin-11300.00%
Return on Equity (ROE8)-165.71%
Return on Assets (ROA9)-115.42%
Avg Volume (3M)93,190
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $33.9M | $10.5M | $17.3M | $7.7M | $488.1K |
| P/E | -1.51 | -0.47 | -0.56 | -0.28 | -0.01 |
| Price/Book | 1.14 | 3.15 | 2.17 | 1.26 | 0.06 |
| EV/EBITDA | — | — | -0.16 | — | — |
| ROE | -75.24% | -664.14% | -389.64% | -454.17% | -591.64% |
| ROA | -61.35% | -199.19% | -213.03% | -201.79% | -304.39% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short166,265
Change from Prior Settlement-13.01%
% of Float—
Days to Cover (Short Ratio)2.05
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-08-13; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -24744.4%. Finnhub fundamentals ↗
- Trailing 52-week price return is -71.3%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CLRB
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$7.2M | -$5.8M | -$4.9M | -$6.0M | -$6.4M | -$13.3M | -$13.7M | -$12.0M |
| Net income | -$6.9M | -$5.7M | -$4.4M | -$5.4M | -$6.6M | -$14.7M | -$919.4K | -$26.6M |
| EPS (diluted) | $-0.57 | $-1.33 | $-1.41 | $-3.39 | $-4.30 | $-12.13 | $-5.43 | $-0.91 |
| EPS (basic) | $-0.57 | $-1.33 | $-1.41 | $-3.39 | $-4.30 | $-11.18 | $-0.77 | $-0.91 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $36.6M | $11.1M | $15.0M | $14.6M | $13.7M | $16.0M | $25.5M | $37.3M |
| Total liabilities | $6.8M | $6.4M | $5.1M | $5.2M | $6.2M | $6.4M | $9.8M | $20.7M |
| Stockholders' equity | $29.9M | $3.3M | $8.5M | $8.0M | $6.1M | $8.3M | $14.3M | $15.2M |
| Total current assets | $34.9M | $9.3M | $14.0M | $13.6M | $12.6M | $14.9M | $24.3M | $35.9M |
| Total current liabilities | $5.2M | $4.9M | $4.7M | $4.9M | $5.9M | $6.0M | $9.4M | $20.3M |
| Cash & equivalents | $34.0M | $8.3M | $13.2M | $12.6M | $11.0M | $13.9M | $23.3M | $34.3M |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $304.2K | $339.7K | $549.4K | $595.3K | $647.5K | $700.8K | $757.1K | $910.1K |
| Goodwill | — | — | — | — | — | — | — | — |
| Other non-current assets | $23.6K | $29.8K | $29.8K | $29.8K | $29.8K | $29.8K | $29.8K | $29.8K |
| Accounts payable | — | — | $1.4M | — | — | — | $4.1M | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $83 | $42 | $42 | $32 | $18 | $461 | $15 | $406 |
| Retained earnings | -$281.7M | -$274.8M | -$269.1M | -$263.8M | -$259.4M | -$253.9M | -$247.3M | -$245.0M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.0M | -$4.8M | -$4.3M | -$4.3M | -$5.1M | -$9.4M | -$10.9M | -$9.2M |
| Investing cash flow | $0 | -$3.4K | -$5.9K | — | — | — | -$61.3K | $0 |
| Financing cash flow | $31.7M | — | $5.0M | $5.8M | $2.3M | — | $0 | $17.6M |
| Free cash flow | -$6.0M | -$4.8M | -$4.4M | — | — | — | -$11.0M | -$9.2M |
| Capital expenditures | $0 | $3.4K | $5.9K | — | — | — | $61.3K | $0 |
| Depreciation & amortization | — | — | $49.5K | $52.3K | $55.6K | $56.3K | $68.6K | $68.6K |
| Share-based compensation | $428.3K | $451.9K | $567.8K | $567.8K | $565.4K | $562.7K | $1.5M | $1.5M |
| Deferred income taxes | — | — | -$6.9M | — | — | — | -$19.6M | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | — | — |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$23.0M | -$51.8M | -$39.0M | -$28.8M | -$24.1M |
| Net income | -$21.8M | -$44.6M | -$42.8M | -$28.6M | -$24.1M |
| EPS (diluted) | $-8.35 | $-41.89 | $-3.50 | $-4.05 | $-4.35 |
| EPS (basic) | $-8.35 | $-36.52 | $-3.50 | $-4.05 | $-4.35 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $15.0M | $25.5M | $12.1M | $21.6M | $37.2M |
| Total liabilities | $5.1M | $9.8M | $25.9M | $6.1M | $4.2M |
| Stockholders' equity | $8.5M | $14.3M | -$15.2M | $8.2M | $33.0M |
| Total current assets | $14.0M | $24.3M | $10.5M | $20.5M | $36.6M |
| Total current liabilities | $4.7M | $9.4M | $25.4M | $5.5M | $4.0M |
| Cash & equivalents | $13.2M | $23.3M | $9.6M | $19.9M | $35.7M |
| Marketable securities (non-current) | — | — | $23.6K | $75.0K | $75.0K |
| Property, plant & equipment | $549.4K | $757.1K | $1.1M | $418.6K | $344.5K |
| Goodwill | — | — | — | — | — |
| Other non-current assets | $29.8K | $29.8K | $29.8K | $6.2K | $6.2K |
| Accounts payable | $1.4M | $4.1M | $5.6M | $2.6M | $1.4M |
| Long-term debt | — | — | — | — | — |
| Common stock & paid-in capital | $42 | $15 | $207 | $94 | $61 |
| Retained earnings | -$269.1M | -$247.3M | -$202.8M | -$179.5M | -$150.9M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$23.1M | -$47.6M | -$32.4M | -$25.2M | -$22.6M |
| Investing cash flow | -$5.9K | -$104.2K | -$864.0K | -$226.0K | -$141.4K |
| Financing cash flow | $13.0M | $61.4M | $22.9M | $9.6M | $1.2M |
| Free cash flow | -$23.1M | -$47.7M | -$33.2M | -$25.4M | -$22.7M |
| Capital expenditures | $5.9K | $104.2K | $864.0K | $226.0K | $141.4K |
| Depreciation & amortization | $213.6K | $291.7K | $192.4K | $148.4K | $149.9K |
| Share-based compensation | $2.3M | $4.3M | $2.4M | $1.5M | $1.1M |
| Deferred income taxes | -$6.9M | -$19.6M | -$15.0M | -$10.4M | -$8.2M |
| Share repurchases | — | — | — | — | — |
| Debt issued | — | — | — | — | — |
| Debt repaid | — | — | — | — | — |
| Other financing activities | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CLRB as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-01-10 to 2026-05-07
Recent transactions
- Insiders have net bought 17,360 shares over the last 182 days, across 2 purchases and 0 sales.
- Most recent: Longcor Jarrod (Chief Operating Officer) — Open market purchase of 8,680 shares on 2026-05-07.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)17,360 sh(2 txns)
Sales (open market)0 sh(0 txns)
Net Shares+17,360
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Longcor Jarrod | Chief Operating Officer | Open market purchase | 2026-05-07 | 8,680 |
| CARUSO JAMES V | Chief Executive Officer | Open market purchase | 2026-05-07 | 8,680 |
| NEIS JOHN | Director | Open market sale | 2025-12-12 | 198 |
| Kolean Chad J | Chief Financial Officer | Open market purchase | 2025-07-02 | 5,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-07 | Longcor Jarrod | Chief Operating Officer | Open market purchase | 8,680 | $2.88 |
| 2026-05-07 | CARUSO JAMES V | Chief Executive Officer | Open market purchase | 8,680 | $2.88 |
| 2025-12-12 | NEIS JOHN | Director | Open market sale | 198 | $3.70 |
| 2025-07-02 | CARUSO JAMES V | Chief Executive Officer | Open market purchase | 10,000 | $4.99 |
| 2025-07-02 | Longcor Jarrod | Chief Operating Officer | Open market purchase | 10,000 | $4.99 |
| 2025-07-02 | Kolean Chad J | Chief Financial Officer | Open market purchase | 5,000 | $4.99 |
| 2025-01-10 | Longcor Jarrod | Chief Operating Officer | Open market purchase | 30,000 | $0.28 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:10 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-10 | 8-K | 2026-07-07 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-07 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-07 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-07 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-07 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-07 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-07 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-07 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-07 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-08 | View on SEC.gov → |
Recent news
Headlines about CLRB (Cellectar Biosciences, Inc.). Links open the publisher — we don’t host full articles.
-
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström
Yahoo · 2026-10-15 -
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
Yahoo Finance · 2026-10-15 -
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
Yahoo Finance · 2026-09-29 -
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript
Yahoo Finance · 2026-08-20 -
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript
Seeking Alpha · 2026-08-18 -
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy - Slideshow
Seeking Alpha · 2026-08-18 -
Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ...
Yahoo Finance · 2026-08-17 -
Cellectar targets mid-2027 accelerated approval NDA for iopofosine in WM, backed by up to $140M financing
Seeking Alpha · 2026-08-13
No headlines in this category right now — try “All”.